Document Detail


A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia.
MedLine Citation:
PMID:  8871266     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This is a report of the results of a two years' randomized, double-blind placebo-controlled study of the efficacy, safety, and tolerability of policosanol administered at 5 mg twice-a-day in the treatment of type II hyperlipoproteinaemia. The study included 69 patients from both sexes, in whom total cholesterol and low-density-lipoprotein cholesterol (LDL-C) were not controlled sufficiently by diet. The treatment effect on total cholesterol and LDL-C was maintained during the 2-year follow up. Thus, percent reductions 24 months after therapy were 25% (LDL-C) and 18% (cholesterol). All comparisons with placebo were significant. Similarly, ratios of LDL-C to HDL-C and cholesterol to HDL-C were significantly reduced and such decreases were maintained during the study. Policosanol raised significantly the values of high-density lipoprotein cholesterol (HDL-C) during the study and maximal increases were reached 12 months after therapy (+21%). From this time the increases mildly declined to +14% and +11.2% respectively at 18 and 24 months after therapy. No significant changes in triglycerides were observed as compared with baseline or placebo. No patient withdrew from the study because of adverse effects. No drug-related clinical or biochemical adverse side-effects were observed. Any adverse experiences reported were mild and transient; moreover, no significant differences were obtained when compared with those reported by the placebo group. The results indicate that policosanol administered for two years to patients with type II hypercholesterolaemia shows a maintained efficacy as well as very good safety and tolerability.
Authors:
M Canetti; M Moreira; R Mas; J Illnait; L Fernandez; J Fernandez; E Diaz; G Castano
Related Documents :
25383946 - A preliminary study on oxya fuscovittata (marschall) as an alternative nutrient supplem...
24210636 - Longevity and diet. myth or pragmatism?
18514906 - Sugar cane policosanol failed to lower plasma cholesterol in primitive, diet-resistant ...
19081406 - Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,...
20166846 - Effect of retorting and oven cooking on the nutritional properties of beef frankfurters...
6778606 - Enhancement of mammary tumorigenesis by dietary selenium deficiency in rats with a high...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  International journal of clinical pharmacology research     Volume:  15     ISSN:  0251-1649     ISO Abbreviation:  Int J Clin Pharmacol Res     Publication Date:  1995  
Date Detail:
Created Date:  1997-02-10     Completed Date:  1997-02-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8110183     Medline TA:  Int J Clin Pharmacol Res     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  159-65     Citation Subset:  IM    
Affiliation:
"Salvador Allende" Hospital, Havana, Cuba.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / adverse effects,  therapeutic use*
Cholesterol, LDL / blood
Double-Blind Method
Fatty Alcohols / adverse effects,  therapeutic use*
Female
Humans
Hyperlipoproteinemia Type II / blood,  drug therapy*
Male
Middle Aged
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Cholesterol, LDL; 0/Fatty Alcohols; 142583-61-7/policosanol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of bezafibrate on HDL with APO A-I and APO A-II and on HDL with APO A-I without APO A-II in h...
Next Document:  Glaucoma and risk factors. Comparative study of cardiovascular risk factors in primary open-angle gl...